2017 Immuno-Oncology Symposium

Matthew Hellmann, MD, Memorial Sloan Kettering and Weill Cornell Medical College, presenting Abstract #77, "Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010"

Orlando, FL - 2017 Clinical Immuno-Oncology Symposium - Matthew Hellmann, MD, Memorial Sloan Kettering and Weill Cornell Medical College, presenting Abstract #77, "Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010," during General Session 3 at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium here today, Thursday, February 23, 2017. The conference, which is a collaboration between the American Society of Clinical Oncology and Society for Immunotherapy of Cancer, is focused on clinical and translational research in immuno-oncology and the implications for clinical care. Photo by © ASCO/Luke Franke 2017